V

Velsera

AI-powered precision medicine data platform

Principal AI Engineer

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Remote in USA
Remote
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • At least 7 years of software engineering experience, including at least 3 years shipping artificial intelligence or machine-learning systems to production.
  • Strong Python skills and proficiency in at least one of Java, Go, or TypeScript; comfort working in a polyglot codebase and conducting production code review.
  • Hands-on experience with secure cloud architecture on at least one major cloud, including network isolation, identity and access management boundaries, private connectivity, and audit logging, and readiness to work across other clouds.
  • Experience operating or integrating model serving across self-hosted open-weight models, managed model APIs, and customer-provided models.
  • MLOps or LLMOps experience with tooling such as AWS Bedrock, Google Vertex AI, Azure AI Foundry, or equivalent.
  • Experience building governance for machine-learning or large-language-model systems, including evaluation, versioning, approvals, rollout and rollback, and deprecation.
  • Comfort designing for regulated or audited environments such as HIPAA, 21 CFR Part 11, GxP, FedRAMP, SOC 2, GDPR, or similar.
  • Experience with retrieval-augmented generation and large-language-model tool-use or agentic patterns beyond prototypes, including evaluating them.
  • Track record integrating with systems the role's team does not own, including existing products, third-party software-as-a-service, and enterprise data sources, without breaking them.
  • Clear written communication for engineering, product, security and compliance, business stakeholders, and scientists.
  • Comfort switching context across problem domains and starting from ambiguous requirements.
Responsibilities
  • Build a governed model access layer for self-hosted open-weight models, cloud-managed models such as Bedrock, Vertex AI, and Azure OpenAI, and customer- or partner-supplied models, designed for consumption by multiple products or business functions.
  • Integrate artificial intelligence capabilities into product experiences and enterprise workflows across batch, interactive, and agentic patterns.
  • Establish reusable patterns for evaluation, versioning, approvals, audit trails, cost control, guardrails, and safe rollout and rollback.
  • Partner with product, engineering, security, quality assurance and regulatory affairs/compliance, information technology, scientific, and commercial teams to introduce adoptable AI-native architectures.
  • Move between assignments as business priorities shift and make what is built in one part of the business usable in another.
  • Deliver a production-ready, compliant AI/large-language-model serving and invocation layer adopted by at least two products or business functions, with multi-tenancy, auditability, and security.
  • Deliver a model governance workflow covering intake, evaluation, approval, versioning, and deprecation that satisfies regulated customers and the company's quality system.
  • Ship two or three AI capabilities end to end in different parts of the business, such as a customer-facing product feature, internal process automation, or assisted validation or compliance tooling.
  • Create integration patterns that preserve reproducibility, traceability, and standards alignment.
  • Establish operational readiness through monitoring, evaluation harnesses, incident playbooks, cost visibility, and measurable service-level objectives for key AI services.
  • Develop an internal position on where the company should build, buy, or avoid AI, supported by shipped work.
  • Set technical direction for the future AI platform and enablement team.
Desired Qualifications
  • Experience in genomics, biomedical data, or life-sciences platforms.
  • Experience building software under a quality management system such as ISO 13485, IEC 62304, or IVDR, or in clinical or diagnostic contexts.
  • Experience integrating AI capabilities into workflow or orchestration engines such as CWL, WDL, or Nextflow.
  • Familiarity with GA4GH standards such as WES, DRS, or TRS, and/or clinical data models such as FHIR or OMOP.
  • Enterprise systems integration experience with CRM, ERP, ITSM, document and quality management, or collaboration suites.
  • Production experience on more than one cloud and pragmatic multi-cloud trade-off judgment.
  • Experience on customer-funded or grant-funded engagements alongside product and services teams.

About the company

Velsera combines AI and data analytics to advance precision medicine in healthcare and life sciences. Its platform collects and analyzes clinical and research data to deliver actionable genomic insights, speeding R&D, democratizing omics, and providing bedside analytics for patient care. It differentiates itself with a continuous knowledge loop between research and clinical practice and adaptive learning that keeps insights current, creating network effects between discoveries and diagnostics. The goal is to accelerate precision medicine by turning research findings into diagnostics and real-time patient insights to improve outcomes.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Velsera

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Kareem Saad joined May 5, 2026 to rebuild commercialization and financial discipline.
  • Velsera keeps landing alliance-led visibility through NVIDIA, Solaris Health, Flywheel, and Arima Genomics.
  • CGW Plus and 14 PB interoperability position Velsera for larger enterprise genomics deployments.

What critics are saying

  • Leadership churn hit twice in 2026: Jamie Coffin replaced Jamie Littlejohns, then Kareem Saad joined.
  • Velsera discloses no funding terms, leaving runway and exit optionality opaque.
  • Illumina, Epic, and Thermo Fisher can bundle genomics workflows and squeeze margins by 2027.

What makes Velsera unique

  • Velsera serves 80+ clinical NGS labs with one genomics-to-clinic workflow.
  • CGW Plus unifies variant review, evidence curation, reporting, and adaptive learning.
  • Its platform bridges research and clinical data, reinforced by CAVATICA interoperability standards.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Unlimited Paid Time Off
  • Health Insurance
  • Life Insurance
  • Mental Health Support
  • Hybrid Work Options
  • Training Programs

Growth & Insights and Company News

6 month growth

-21%

1 year growth

-21%

2 year growth

-21%
Velsera
May 5th, 2026
Velsera appoints Kareem Saad as President and Chief Business Officer to accelerate next phase of growth.

Velsera appoints Kareem Saad as President and Chief Business Officer to accelerate next phase of growth. By Johanna Samuelsson Boston, May 5, 2026 - Velsera, a leading global healthcare technology company advancing precision medicine, today announced the appointment of Kareem Saad as President and Chief Business Officer. In this role, Saad will lead all commercial and business functions globally across the organization, helping drive Velsera's transition from stabilization to sustained growth as the adoption of precision medicine continues to accelerate in the U.S. and globally. Mr. Saad brings extensive leadership experience building and scaling commercial organizations, alongside deep expertise overseeing strategic finance functions across both large enterprises and high-growth companies in the precision medicine and broader healthcare ecosystem. His track record includes driving revenue expansion, optimizing go-to-market strategies, and aligning financial and operational performance to support long-term value creation. Mr. Saad has also successfully led $4B+ in strategic transactions in the precision medicine space across the spectrum of corporate development and strategic financings. At Velsera, Mr. Saad will be responsible for bolstering the company's financial foundation, advancing its commercial strategy, strengthening customer engagement, and unlocking new growth opportunities across its portfolio of data-driven solutions that enable personalized healthcare. "I'm incredibly excited to join Velsera at such a pivotal moment," said Kareem Saad. "The company has built a strong foundation, and I'm energized by the opportunity to work with the strong team in place to accelerate its next phase of growth. As precision medicine continues to gain momentum across the healthcare landscape, I'm very bullish on Velsera's ability to play a central role in shaping that future - both in the U.S. and globally." Jamie Coffin, Chief Executive Officer of Velsera, added, "We are thrilled to welcome Kareem to Velsera. He is a proven leader with a unique combination of commercial acumen and financial discipline, and his experience across organizations of varying scale will be invaluable as we continue to grow. On a personal note, I'm especially excited to be joining forces with Kareem again - his leadership, energy, and strategic mindset make him the ideal partner for this next chapter." Mr. Saad's appointment underscores Velsera's commitment to strengthening its leadership team as it builds on recent progress and positions itself to capitalize on the expanding role of precision medicine in transforming healthcare delivery. About Velsera Velsera is a global healthcare technology company dedicated to advancing precision medicine by connecting complex data with innovative analytics and clinical insights. The company partners with biopharma, diagnostics, and healthcare organizations to improve patient outcomes and accelerate the development and delivery of personalized therapies. Media Contact:

Financial Post
Jun 27th, 2024
Genetic Sequence Data Analysis & Reporting Accelerated with Velsera's Release of CGW Plus

BOSTON - Velsera, a leading global healthcare technology company offering a universal software platform to connect clinical care with discovery, is thrilled to announce the launch of CGW Plus, its reimagined Clinical Genomics Workspace (CGW) platform.

Business Wire
Apr 4th, 2024
Velsera And Flywheel Team Up To Support Multimodal Imaging Genomics Research

BOSTON--(BUSINESS WIRE)--Velsera, a global healthcare technology company that offers leading biomedical data analysis platforms, has joined forces with Flywheel, the leading medical imaging management and artificial intelligence (AI) development platform, and the Center for Data-Driven Discovery in Biomedicine (D3b) based at Children’s Hospital of Philadelphia, to advance the analysis of large-scale genomics and medical imaging datasets. In this collaborative pilot effort through the NIH-wide INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project, the partners combined their expertise to unite the Velsera CAVATICA platform and the Flywheel Core Platform, providing unprecedented capabilities to scale multimodal data analysis with clear pathways to advance precision medicine programs across government and pharmaceutical sectors. While extensive amounts of genomic and imaging data are being amassed in the healthcare system today, researchers struggle to combine this data in ways that could help make the discovery of new treatments faster and more precise. Limitations include access obstacles, privacy concerns, and integration and computational requirements for such large datasets. Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.The Velsera team created interoperability standards that allow platforms to communicate with each other and make large-scale data access transparent to the user. These interoperability standards make 14 PB of data accessible from the Velsera platform ecosystem.The Flywheel platform uses containerized algorithms to de-identify images, run QC workflows, and consistently curate data to facilitate large-scale sharing and analysis of imaging data sets.The D3b team provided vision of AI and imaging data, subject matter expertise in health data and bioinformatics analysis pipelines, and, within the NIH-funded INCLUDE Data Coordinating Center and Office of Data Science Strategy, FHIR proficiency critical for data harmonization.“Linking our Flywheel Core Platform with Velsera’s CAVATICA platform facilitates an unparalleled ability to perform advanced, multimodal data analysis in a cloud environment,” said Travis Richardson, Chief Strategist at Flywheel

BioCentury
Mar 7th, 2024
Sandoz names new CFO, board nominations

Computational biology company Velsera Inc. named Jamie Littlejohns CEO, succeeding interim CEO Hans Cobben, who remains chairman.

Business Wire
Mar 5th, 2024
Velsera Announces Appointment Of Jamie Littlejohns As New Chief Executive Officer

BOSTON--(BUSINESS WIRE)--Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024. Jamie is set to succeed Hans Cobben, who has served as the interim CEO and will revert to his position as Chairman of the Board at Velsera. Jamie joins Velsera from his previous role at McKinsey, where he was a Partner and led McKinsey’s European Healthcare Life Science Private Equity Practice. He has worked in Healthcare and Life Sciences since 2010 across Europe, the US and Australia and has developed expertise in supporting investor-backed health life science tech companies on their scale-up journeys. Although new to Velsera in a full-time capacity, Jamie has been part of Velsera’s journey since early 2022 through his support in an external advisory capacity. In his own words, Jamie says, "I am thrilled to be joining the wonderful team at Velsera